

FUJIFILM Toyama Chemical enters agreement with Appili Therapeutics regard to assigning rights for the development and marketing of T-2307, a candidate compound for the treatment of fungal diseases.

Tokyo, November 21, 2019 — FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada) announced today it has entered an agreement with Appili Therapeutics (“Appili”) regarding the assignment of rights for the development and marketing of T-2307 outside of Japan. Subject to terms of the agreement, FUJIFILM Toyama Chemical will transfer the development and marketing rights of the compound to Appili and receive milestones payments as well as royalties in the future.

T-2307, an antifungal candidate compound developed by FUJIFILM Toyama Chemical, exhibits its antifungal activity through a novel mode of action whereby it actively accumulates in fungal cells^{*1} and is designed to selectively disrupt the function of fungal mitochondria^{*2}.

In the course of R&D with primary focus of targeting fungi, FUJIFILM Toyama Chemical has discovered and developed T-2307 for the treatment of various mycoses^{*3} including those due to drug resistant strains. The company continued to conduct clinical development of T-2307, including Phase I clinical trials in the United States.

Appili established in 2015 in Canada, is engaged in the R&D of drugs specializing in the area of infectious diseases. The company was listed in July 2019 on the Toronto Stock Exchange, and has been accelerating the development of new drugs. Through conclusion of this agreement, Appili plans to carry out a Phase II clinical trial of T-2307 targeting cryptococcal meningitis^{*4}, a disease for which an effective treatment drug is being sought.

FUJIFILM Toyama Chemical has been promoting the R&D of treatment drugs with unique mode of action, focusing on “infectious diseases” as one of the key areas.

The agreement will contribute to solving social issues through the provision of innovative and high value-added drugs through the cooperation of Appili and FUJIFILM Toyama Chemical and also would widen the physician’s choice by treating fungal infections as well as the treatment options of the patient.

*1 Microorganisms called "mold" or "yeast". The majority of fungi are harmless to healthy individuals, but may cause mycoses in immunocompromised conditions.

*2 Organelles found in most eukaryotic cells. Mitochondria are membrane-bound cell organelles that generate most of the chemical energy needed to power the cell's biochemical reactions.

*3 An infection caused by a fungus that enters deep areas of the body such as the lungs, liver and the brain. It is a type of opportunistic infection, caused by pathogens that do not occur in healthy individuals, but develop in patients whose immune system has declined because of immunocompromised condition in case of bone marrow or organ transplants, long term administration

